CN1413731A - Macrophage tumor vaccin and its preparation method - Google Patents
Macrophage tumor vaccin and its preparation method Download PDFInfo
- Publication number
- CN1413731A CN1413731A CN 02131743 CN02131743A CN1413731A CN 1413731 A CN1413731 A CN 1413731A CN 02131743 CN02131743 CN 02131743 CN 02131743 A CN02131743 A CN 02131743A CN 1413731 A CN1413731 A CN 1413731A
- Authority
- CN
- China
- Prior art keywords
- tumor
- macrophage
- cell
- vaccine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A macrophage vaccine for tumor is prepared through culturing the deactivated autogenous or heterogenous tumor cells and the mononuclear cells obtained from blood or abdominal cavity, activating the precursor cells of macrophage, splitting for reproducing while englobing the tumor cells, and using the macrophage to prepare the tumor vaccine. Its advantages are high antineoplastic effect, simple process and low cost.
Description
Specificity active immunotherapy treatment tumor has certain curative effect for many institutes confirm, tumor vaccine how to prepare high antigen presentation is the key that improves this therapy curative effect.At present, the tumor vaccine that is in the clinical research stage mainly contains autologous tumor cell tumor vaccine, heat shock protein peptide complex tumor vaccine and the dendritic cell-based tumor vaccines etc. of modification.Tumor-cell antigen is one of the tumor cell important mechanisms that can not bring out immunoreation and escape immune surveillance effectively a little less than, though tumor cell can promote the allosteric or the coupling of cell cortex protein through suitable chemical factors effect, or make the foreign body increase of tumor cell with means such as virus transfection and transgenic, to improve antigenicity of tumor cell, but these method of modifying fundamentally do not change tumor cell surface MHC1 quasi-molecule expression decreased, and tumor antigen can not be expressed in the drawback of cell surface.Heat shock protein peptide complex tumor vaccine and dendritic cell-based tumor vaccines are respectively to utilize the tumor tumor vaccine of the heat shock protein peptide complex preparation with utilizing tumor cell or its content and DC mixing with cells to cultivate that is separated to from tumor cell, though these tumor Seedling tumor vaccine can overcome a little less than the tumor-cell antigen and can not be used for allochthonous drawback, but the separation and Extraction more complicated of heat shock protein peptide complex and DC precursor, and expense is higher, is unsuitable for clinical practice.
This invention be for preparation and set up a kind of effectively and be convenient to tumor vaccine of clinical practice and preparation method thereof.Macrophage is the main cleaning cell of body pathogenic microorganism and slough, and has the antigen presentation function, specific immune response bring out with process of immune regulation in play a crucial role.The macrophage tumor vaccin that adopts the activated macrophage of deactivation tumor cell and prepare can overcome tumor cell and express drawback a little less than not enough, the antigenicity because of surface antigen, improve the anti-tumor effect of tumor vaccine.I find in acidity and do not need to add under the condition of any foreign cell factor that dead cell can make macrophage or its precursor activation and proliferation.With mixing with the mononuclearcell that is separated to from peripheral blood or abdominal cavity of deactivation from body or allogeneic tumor cell, place 37 ℃, 5%CO2 incubator, after cell enters quick splitting status, conventional method is changed liquid and is gone down to posterity, when tumor cell is almost all engulfed, collect giant cell, the washing back is used for intradermal vaccination with sugared normal saline furnishing finite concentration in batches.That this method has is simple to operate, preparation cost is low and be convenient to the characteristics of clinical practice.
Claims (3)
1. tumor vaccine that adopts macrophage preparation.
2. method that adopts macrophage to prepare tumor vaccine, it is characterized in that with deactivation from body or allogeneic tumor cell and the mononuclearcell Mixed culture of collecting from blood or abdominal cavity, utilize the macrophage of engulfing tumor cell to prepare tumor vaccine.
3. as method as described in the right 2, it is characterized in that utilizing the acid condition due to the cellular metabolism, the precursor of dead cell activating macrophage makes its division growth and engulfs dead cell, does not need special separation macrophage and its precursor and adds any exogenous cytokine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02131743 CN1413731A (en) | 2002-09-17 | 2002-09-17 | Macrophage tumor vaccin and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02131743 CN1413731A (en) | 2002-09-17 | 2002-09-17 | Macrophage tumor vaccin and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1413731A true CN1413731A (en) | 2003-04-30 |
Family
ID=4746711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02131743 Pending CN1413731A (en) | 2002-09-17 | 2002-09-17 | Macrophage tumor vaccin and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1413731A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100354002C (en) * | 2005-05-31 | 2007-12-12 | 中国人民解放军第三军医大学第一附属医院 | New type of cell vaccine with heteroimmune cell as cell vector and its prepn process |
| CN106267174A (en) * | 2016-08-04 | 2017-01-04 | 大连大学 | The preparation method of M1 macrophage tumor vaccin |
| WO2020038299A1 (en) * | 2018-08-20 | 2020-02-27 | 中国科学院过程工程研究所 | Exosome-based antitumor vaccine |
-
2002
- 2002-09-17 CN CN 02131743 patent/CN1413731A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100354002C (en) * | 2005-05-31 | 2007-12-12 | 中国人民解放军第三军医大学第一附属医院 | New type of cell vaccine with heteroimmune cell as cell vector and its prepn process |
| CN106267174A (en) * | 2016-08-04 | 2017-01-04 | 大连大学 | The preparation method of M1 macrophage tumor vaccin |
| WO2020038299A1 (en) * | 2018-08-20 | 2020-02-27 | 中国科学院过程工程研究所 | Exosome-based antitumor vaccine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110564682B (en) | Method for large-scale production of human adipose-derived mesenchymal stem cell exosomes | |
| CN103756962A (en) | Method used for in vitro amplification of gamma-delta-T cells | |
| ES2407150T3 (en) | Novel lactic acid bacterium with anti-allergic activity, anti-allergic agent, food and pharmaceutical composition comprising, each of them, lactic acid bacteria, and process for the production of the anti-allergic agent | |
| CN101954073A (en) | Novel anti-tumor cell vaccine and preparation method thereof | |
| CN109998998A (en) | A kind of nano vaccine and preparation method thereof | |
| CN107164332A (en) | Leukaemia's excretion body that the TGF β 1 modified through interference sequence keep silent and its preparation method and application | |
| CN106591231B (en) | BCG polysaccharide nucleic acid for promoting proliferation and differentiation of CIK cells, culture medium, culture method and application | |
| WO2014021070A1 (en) | Method for obtaining monocytes or nk cells | |
| CN103789265A (en) | Method for efficiently separating and culturing hippocampal neurons | |
| CN107488235A (en) | A kind of preparation and application of new enhanced antigen combined polypeptid induction liver cancer-specific CTL cells | |
| CN103805565B (en) | Hippocampal neuron is separated and primary culture method and reagent | |
| CN103789268B (en) | A kind of method of separation and Culture hippocampal neurons and special culture solution thereof | |
| CN103789267B (en) | A kind of improved primary hippocampal neurons method | |
| CN108300692A (en) | A method of preparing HPV Antigen-specific cytotoxic T lymphocytes | |
| CN103981144A (en) | Preparation method for autologous-serum antigen-sensitized DC-CIK cells | |
| AU2020103625A4 (en) | Applications of bacillus calmette-guerin (bcg) polysaccharide and nucleic acid in in-vitro culture of cytokine-induced-killer (cik) cells and preparation of antitumor drugs | |
| CN1413731A (en) | Macrophage tumor vaccin and its preparation method | |
| CN108558998A (en) | Porcine IL-4/6 co-express the preparation and application of recombination yeast bacteria preparation with pig antibacterial peptide is merged | |
| CN202107707U (en) | CIK (cytokine induced killer) cell induction activating reagent kit | |
| CN107312751A (en) | Special culture medium and culture method for inducing stable differentiation of mouse bone marrow cells into immature dendritic cells | |
| CN116948901A (en) | Application of Weissella antrum D-2 extracellular polysaccharide in inhibiting colon cancer cells | |
| Sportès et al. | Perspective on potential clinical applications of recombinant human interleukin‐7 | |
| CN105087489A (en) | DC cell culture reagent and culture method thereof | |
| CN115896016A (en) | Culture composition and application thereof in culturing immune cells | |
| CN107502591A (en) | The iNKT methods for cell expansion and its application that a kind of concentration gradient rhIL 2 is relied on |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |